Pfizer Completes Acquisition of Metsera for $7.0 Billion

Pfizer completes acquisition of Metsera, a clinical-stage biopharmaceutical company, for $7.0 billion. The acquisition adds a portfolio of promising therapeutic candidates to Pfizer's Internal Medicine pipeline. Pfizer will combine Metsera's innovative portfolio with its global development, manufacturing, and commercial infrastructure to advance candidate therapies for obesity and cardiometabolic diseases. The acquisition is expected to be dilutive through 2030, but will enable further investment in late-stage pipeline candidates.